|Day Low/High||94.70 / 96.05|
|52 Wk Low/High||58.59 / 98.97|
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
These stocks and sectors are safe havens, and may even be opportunities.
Here we break down the numbers of some of the company's top drugs, but we now only have 175 shares remaining in this tag end of a position, as there are better health care stocks in the market right now.
Drugmaker Celgene reports second-quarter adjusted earnings and revenue that beat analysts' forecasts and raises its guidance through the remainder of the year amid strong sales of its cancer and other disease-fighting treatments.
Celgene Corporation (NASDAQ: CELG) reported second quarter 2019 total revenue of $4,400 million, a 15 percent increase compared to $3,814 million in the second quarter of 2018.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has granted unconditional approval of Bristol-Myers Squibb's pending acquisition of Celgene Corporation (NASDAQ:CELG).
Jounce Therapeutics and Ocular Therapeutix each provided investors with positive news morsels last week.
Here's the only way to explain why stocks jump like mad if the companies underneath them only perform slightly better than the analysts worried they would.
Edward Jones' Investment Strategist says Q3 and Q4 earnings season will be solid but not spectacular. Here's why.
Bristol-Myers Squibb posts stronger-than-expected second-quarter earnings and boost its full-year profit forecast while adding that its $74 billion acquisition of Celgene would likely close in early 2020.
And as the semiconductor sector continues to shine, Brooks Automation is a name to keep in mind.
Celgene Corporation (NASDAQ: CELG) and the Multiple Sclerosis Association of America (MSAA) are bringing the MS MindShift: A New View of MS initiative to the 37 th Annual QuickChek New Jersey Festival of Ballooning in Readington, NJ, on July 26-28, where...
U.S. stock futures are lower as U.S.-China trade talks are set to resume; the Department of Justice launches a new probe into whether Alphabet, Amazon, Facebook and Apple have been stifling competition; Tesla, Boeing, Ford, Facebook and Caterpillar report earnings.
Celgene Corporation (NASDAQ:CELG) today announced that the U.S.
Shares of Gilead Sciences are jumping higher on its increased investment in Galapagos and a new outperform rating from Wells Fargo.
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
Watch the Russell 2000, housing activity, and mergers and acquisitions.
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
Stocks end little changed Monday as investors look to the upcoming G-20 summit for a breakthrough in talks between the world's two largest economies.
Let's check out the charts of BMY.
Bristol-Myers Squibb slumped to the bottom of the S&P 500 Monday after the group said the U.S. Federal Trade Commission was still looking into its proposed $74 billion takeover of cancer specialist Celgene and that it would sell that company's psoriasis to push the deal through.
U.S. stocks look set to test all time highs again Monday, following a third consecutive weekly gain for all three benchmarks on Wall Street, as investors continue to bet that central bank support will boost global equities and this weekend's G20 Summit in Osaka will trigger a breakthrough in U.S.-China trade talks.
Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company's pending merger with Celgene Corporation (NASDAQ: CELG).
These two firms have successful drugs and could make nice additions for larger companies.
Pfizer said Monday it has agreed to acquire Array Biopharma in an all-cash deal that values the cancer drug specialist at around $11.4 billion.
Winner selected for potential of innovation to impact people with multiple sclerosis (MS) and their care partners
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.